FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:707-715 March 14, 1996 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article PubMed Citation

The female steroid hormones, estrogen and progesterone, are prescribed widely by physicians, and their risks and benefits have been studied extensively. Although androgen preparations have been available for many years, most clinicians are less familiar with these hormones, and their risks and benefits have received less attention. The most common indication for androgen therapy is hypogonadism in men, but other potential uses of androgens are being explored. In addition, androgen abuse has become common among athletes and bodybuilders. It is therefore important that physicians be aware of the physiology, pharmacology, clinical indications, and adverse effects of androgens.

Physiology

The hypothalamus secretes . . . [Full Text of this Article]

Biologic Effects

Reproductive Tissues

Sexual Function and Behavior

Muscle

Skin and Hair

Liver

Lipids

Bone

Hematologic and Immunologic Effects

Androgen Preparations

Currently Available Preparations

Experimental Delivery Systems

Clinical Indications

Hypogonadism in Adults

Delayed Puberty

Hematologic Disorders

Hereditary Angioedema

Endometriosis

Experimental Uses

            Aging

            Male Contraception

Abuse of Androgens

Epidemiology and Patterns of Use

Effects on Strength and Performance

Complications and Side Effects

Side Effects during Androgen Replacement

Complications and Side Effects of Supraphysiologic Doses of Androgens

Conclusions

Source Information

From the Veterans Affairs Medical Center and the Department of Medicine, University of Washington School of Medicine, Seattle.

Address reprint requests to Dr. Bagatell at Endocrinology (111), VA Medical Center, 1660 S. Columbian Way, Seattle, WA 98108.

References

This article has been cited by other articles:

• Laghi, F., Adiguzel, N., Tobin, M. J. (2009). Endocrinological derangements in COPD. Eur Respir J 34: 975-996 [Abstract] [Full Text]  
• Almeida, O. P., Yeap, B. B., Hankey, G. J., Jamrozik, K., Flicker, L. (2008). Low Free Testosterone Concentration as a Potentially Treatable Cause of Depressive Symptoms in Older Men. Arch Gen Psychiatry 65: 283-289 [Abstract] [Full Text]  
• Khaw, K.-T., Dowsett, M., Folkerd, E., Bingham, S., Wareham, N., Luben, R., Welch, A., Day, N. (2007). Endogenous Testosterone and Mortality Due to All Causes, Cardiovascular Disease, and Cancer in Men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116: 2694-2701 [Abstract] [Full Text]  
• Nettleship, J. E., Jones, T. H., Channer, K. S., Jones, R. D. (2007). Physiological Testosterone Replacement Therapy Attenuates Fatty Streak Formation and Improves High-Density Lipoprotein Cholesterol in the Tfm Mouse: An Effect That Is Independent of the Classic Androgen Receptor. Circulation 116: 2427-2434 [Abstract] [Full Text]  
• Cantin, L., Faucher, F., Couture, J.-F., de Jesus-Tran, K. P., Legrand, P., Ciobanu, L. C., Frechette, Y., Labrecque, R., Singh, S. M., Labrie, F., Breton, R. (2007). Structural Characterization of the Human Androgen Receptor Ligand-binding Domain Complexed with EM5744, a Rationally Designed Steroidal Ligand Bearing a Bulky Chain Directed toward Helix 12. J. Biol. Chem. 282: 30910-30919 [Abstract] [Full Text]  
• Ries, A. L., Bauldoff, G. S., Carlin, B. W., Casaburi, R., Emery, C. F., Mahler, D. A., Make, B., Rochester, C. L., ZuWallack, R., Herrerias, C. (2007). Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 131: 4S-42S [Abstract] [Full Text]  
• Perera, M. A., Yin, D., Wu, D., Chan, K. K., Miller, D. D., Dalton, J. (2006). In Vivo Metabolism and Final Disposition of a Novel Nonsteroidal Androgen in Rats and Dogs. Drug Metab. Dispos. 34: 1713-1721 [Abstract] [Full Text]  
• Rabkin, J. G., McElhiney, M. C., Rabkin, R., McGrath, P. J., Ferrando, S. J. (2006). Placebo-Controlled Trial of Dehydroepiandrosterone (DHEA) for Treatment of Nonmajor Depression in Patients With HIV/AIDS. Am. J. Psychiatry 163: 59-66 [Abstract] [Full Text]  
• Kim, J., Wu, D., Hwang, D. J., Miller, D. D., Dalton, J. T. (2005). The Para Substituent of S-3-(Phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamides Is a Major Structural Determinant of in Vivo Disposition and Activity of Selective Androgen Receptor Modulators. J. Pharmacol. Exp. Ther. 315: 230-239 [Abstract] [Full Text]  
• Rau, K-M, Kang, H-Y, Cha, T-L, Miller, S A, Hung, M-C (2005). The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer 12: 511-532 [Abstract] [Full Text]  
• Hall, R. C.W., Hall, R. C.W., Chapman, M. J. (2005). Psychiatric Complications of Anabolic Steroid Abuse. Psychosomatics 46: 285-290 [Abstract] [Full Text]  
• Galobardes, B., Smith, G. D., Jeffreys, M., Kinra, S., McCarron, P. (2005). Acne in Adolescence and Cause-specific Mortality: Lower Coronary Heart Disease but Higher Prostate Cancer Mortality: The Glasgow Alumni Cohort Study. Am J Epidemiol 161: 1094-1101 [Abstract] [Full Text]  
• Amory, J. K., Bremner, W. J. (2005). Oral Testosterone in Oil Plus Dutasteride in Men: A Pharmacokinetic Study. J. Clin. Endocrinol. Metab. 90: 2610-2617 [Abstract] [Full Text]  
• Laghi, F., Antonescu-Turcu, A., Collins, E., Segal, J., Tobin, D. E., Jubran, A., Tobin, M. J. (2005). Hypogonadism in Men with Chronic Obstructive Pulmonary Disease: Prevalence and Quality of Life. Am. J. Respir. Crit. Care Med. 171: 728-733 [Abstract] [Full Text]  
• Laghi, F., Langbein, W. E., Antonescu-Turcu, A., Jubran, A., Bammert, C., Tobin, M. J. (2005). Respiratory and Skeletal Muscles in Hypogonadal Men with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 171: 598-605 [Abstract] [Full Text]  
• Brown, T. R. (2004). Nonsteroidal Selective Androgen Receptors Modulators (SARMs): Designer Androgens with Flexible Structures Provide Clinical Promise. Endocrinology 145: 5417-5419 [Full Text]  
• Nieschlag, E., Behre, H.M., Bouchard, P., Corrales, J.J., Jones, T.H., Stalla, G.K., Webb, S.M., Wu, F.C.W. (2004). Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10: 409-419 [Abstract] [Full Text]  
• Morgentaler, A. (2004). A 66-Year-Old Man With Sexual Dysfunction. JAMA 291: 2994-3003 [Full Text]  
• Evans, N. A. (2004). Current Concepts in Anabolic-Androgenic Steroids. Am J Sports Med 32: 534-542 [Abstract] [Full Text]  
• Rhoden, E. L., Morgentaler, A. (2004). Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. NEJM 350: 482-492 [Full Text]  
• Sathya, G., Chang, C.-y., Kazmin, D., Cook, C. E., McDonnell, D. P. (2003). Pharmacological Uncoupling of Androgen Receptor-mediated Prostate Cancer Cell Proliferation and Prostate-specific Antigen Secretion. Cancer Res. 63: 8029-8036 [Abstract] [Full Text]  
• Navarro, J. F. (2003). In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrol Dial Transplant 18: 2222-2226 [Full Text]  
• Yin, D., Gao, W., Kearbey, J. D., Xu, H., Chung, K., He, Y., Marhefka, C. A., Veverka, K. A., Miller, D. D., Dalton, J. T. (2003). Pharmacodynamics of Selective Androgen Receptor Modulators. J. Pharmacol. Exp. Ther. 304: 1334-1340 [Abstract] [Full Text]  
• Nahrendorf, M., Frantz, S., Hu, K., von zur Muhlen, C., Tomaszewski, M., Scheuermann, H., Kaiser, R., Jazbutyte, V., Beer, S., Bauer, W., Neubauer, S., Ertl, G., Allolio, B., Callies, F. (2003). Effect of testosterone on post-myocardial infarction remodeling and function. Cardiovasc Res 57: 370-378 [Abstract] [Full Text]  
• Yin, D., He, Y., Perera, M. A., Hong, S. S., Marhefka, C., Stourman, N., Kirkovsky, L., Miller, D. D., Dalton, J. T. (2003). Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor. Mol. Pharmacol. 63: 211-223 [Abstract] [Full Text]  
• Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., McKinlay, J. B. (2002). Age Trends in the Level of Serum Testosterone and Other Hormones in Middle-Aged Men: Longitudinal Results from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 87: 589-598 [Abstract] [Full Text]  
• Luzardo, O. P., Machin, R. P., Diaz-Chico, B. N., Fernandez, L. (2000). Photoaffinity Labeling Identification of a Specific Binding Protein for the Anabolic Steroids Stanozolol and Danazol: An Oligomeric Protein Regulated by Age, Pituitary Hormones, and Ethinyl Estradiol. Endocrinology 141: 3377-3387 [Abstract] [Full Text]  
• Struijs, A., Smals, A., de Witte, S. A., Hackeng, W. H. L., Mulder, H. (2000). Acute effects of etidronate on glucocorticoid-induced bone degradation. Rheumatology (Oxford) 39: 523-529 [Abstract] [Full Text]  
• Casaburi, R. (2000). Skeletal Muscle Function in COPD. Chest 117 : 267S-271S [Abstract] [Full Text]  
• Demark-Wahnefried, W., Schildkraut, J. M., Thompson, D., Lesko, S. M., McIntyre, L., Schwingl, P., Paulson, D. F., Robertson, C. N., Anderson, E. E., Walther, P. J. (2000). Early Onset Baldness and Prostate Cancer Risk. Cancer Epidemiol. Biomarkers Prev. 9: 325-328 [Abstract] [Full Text]  
• Goldstein, M. F., Fallon, J. J. Jr, Harning, R. (1999). Chronic Glucocorticoid Therapy-Induced Osteoporosis in Patients With Obstructive Lung Disease*. Chest 116: 1733-1749 [Abstract] [Full Text]  
• Gori, F., Hofbauer, L. C., Conover, C. A., Khosla, S. (1999). Effects of Androgens on the Insulin-Like Growth Factor System in an Androgen-Responsive Human Osteoblastic Cell Line. Endocrinology 140: 5579-5586 [Abstract] [Full Text]  
• Webb, C. M., McNeill, J. G., Hayward, C. S., de Zeigler, D., Collins, P. (1999). Effects of Testosterone on Coronary Vasomotor Regulation in Men With Coronary Heart Disease. Circulation 100: 1690-1696 [Abstract] [Full Text]  
• Negro-Vilar, A. (1999). Selective Androgen Receptor Modulators (SARMs): A Novel Approach to Androgen Therapy for the New Millennium. J. Clin. Endocrinol. Metab. 84: 3459-3462 [Full Text]  
• Alexandersen, P., Haarbo, J., Byrjalsen, I., Lawaetz, H., Christiansen, C. (1999). Natural Androgens Inhibit Male Atherosclerosis : A Study in Castrated, Cholesterol-Fed Rabbits. Circ. Res. 84: 813-819 [Abstract] [Full Text]  
• (1999). Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease . A Statement of the American Thoracic Society and European Respiratory Society. Am. J. Respir. Crit. Care Med. 159: S2-40 [Full Text]  
• Lewis, M. I., Fournier, M., Yeh, A. Y., Micevych, P. E., Sieck, G. C. (1999). Alterations in diaphragm contractility after nandrolone administration: an analysis of potential mechanisms. J. Appl. Physiol. 86: 985-992 [Abstract] [Full Text]  
• Cummings, D. E., Kumar, N., Bardin, C. W., Sundaram, K., Bremner, W. J. (1998). Prostate-Sparing Effects in Primates of the Potent Androgen 7{alpha}-Methyl-19-Nortestosterone: A Potential Alternative to Testosterone for Androgen Replacement and Male Contraception. J. Clin. Endocrinol. Metab. 83: 4212-4219 [Abstract] [Full Text]  
• Bagatell, C. J., Bremner, W. J. (1998). V. The Effects of Aging and Testosterone on Lipids and Cardiovascular Risk. J. Clin. Endocrinol. Metab. 83: 3440-3441 [Full Text]  
• Smyth, C. M., Bremner, W. J. (1998). Klinefelter Syndrome. Arch Intern Med 158: 1309-1314 [Abstract] [Full Text]  
• Weidemann, W., Peters, B., Romalo, G., Spindler, K.-D., Schweikert, H.-U. (1998). Response to Androgen Treatment in a Patient with Partial Androgen Insensitivity and a Mutation in the Deoxyribonucleic Acid-Binding Domain of the Androgen Receptor. J. Clin. Endocrinol. Metab. 83: 1173-1176 [Abstract] [Full Text]  
• Dunaif, A. (1997). Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis. Endocr. Rev. 18: 774-800 [Abstract] [Full Text]  
• Luppa, P., Bruckner, C., Schwab, I., Hauck, S., Schmidmayr, S., Birkmayer, C., Paulus, B., Hauptmann, H. (1997). 7{alpha}-Biotinylated testosterone derivatives as tracers for a competitive chemiluminescence immunoassay of testosterone in serum. Clin. Chem. 43: 2345-2352 [Abstract] [Full Text]  
• Lamberts, S. W., van den Beld, A. W., van der Lely, A. (1997). The Endocrinology of Aging. Science 278: 419-424 [Abstract] [Full Text]  
• Franke, W. W., Berendonk, B. (1997). Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin. Chem. 43: 1262-1279 [Abstract] [Full Text]  
• Zacharin, M R, Warne, G L (1997). Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Arch. Dis. Child. 76: 495-499 [Abstract] [Full Text]  
• Bhasin, S., Storer, T. W., Berman, N., Yarasheski, K. E., Clevenger, B., Phillips, J., Lee, W. P., Bunnell, T. J., Casaburi, R. (1997). Testosterone Replacement Increases Fat-Free Mass and Muscle Size in Hypogonadal Men. J. Clin. Endocrinol. Metab. 82: 407-413 [Abstract] [Full Text]  
• Bhasin, S., Bremner, W. J. (1997). Emerging Issues in Androgen Replacement Therapy. J. Clin. Endocrinol. Metab. 82: 3-8 [Full Text]  
• Mitch, W. E., Goldberg, A. L. (1996). Mechanisms of Muscle Wasting -- The Role of the Ubiquitin-Proteasome Pathway. NEJM 335: 1897-1905 [Full Text]  
• Weksler, M. E (1996). Hormone replacement for men. BMJ 312: 859-860 [Full Text]